Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update [Yahoo! Finance]
Assessing Immunovant (IMVT) Valuation As Shares Deliver A 25% One Year Return [Yahoo! Finance]
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.